Circulating high-molecular-weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function

Mathias Fasshauer1,2, Theresa Waldeyer3, Jeannette Seeger1, Susanne Schrey3, Thomas Ebert1, Jürgen Kratzsch4, Ulrike Lössner1, Matthias Blüher1, Michael Stumvoll1, Renaldo Faber3 and Holger Stepan1

1Department of Internal Medicine III, University of Leipzig, Ph.-Rosenthal-Str. 27, 04103 Leipzig, Germany, 2Interdisciplinary Center for Clinical Research (IZKF) Leipzig, 04103 Leipzig, Germany, 3Department of Obstetrics and 4Institute of Laboratory Medicine, University of Leipzig, 04103 Leipzig, Germany

(Correspondence should be addressed to M Fasshauer; Email: mathias.fasshauer@medizin.uni-leipzig.de)

Abstract

Objective: Preeclampsia (PE) is a serious cardiovascular complication in pregnancy which is associated with an increased future metabolic and cardiovascular risk for mother and newborn. Recently, a paradoxical upregulation of the insulin-sensitizing and anti-atherogenic adipokine adiponectin has been shown in PE. Furthermore, high-molecular-weight (HMW) adiponectin has been suggested as the biologically active form of this adipokine.

Design and methods: HMW adiponectin and total adiponectin serum concentrations were quantified by ELISA in PE (n = 16) patients and pregnant control women without PE (n = 20). Furthermore, HMW adiponectin and total adiponectin were correlated to clinical and biochemical measures of renal function, glucose, and lipid metabolism, as well as inflammation.

Results: Median maternal HMW adiponectin and total adiponectin levels were significantly and independently upregulated almost twofold in PE when compared with controls. HMW adiponectin and total adiponectin correlated positively with creatinine and negatively with fasting insulin in univariate and multivariate analyses.

Conclusions: We show that maternal HMW adiponectin and total adiponectin serum concentrations are significantly increased in PE and are positively associated with markers of insulin sensitivity and renal dysfunction. Adiponectin might be part of a physiological feedback mechanism improving insulin sensitivity and cardiovascular health in PE.

European Journal of Endocrinology 158 197–201

Introduction

Preeclampsia (PE), which is characterized by hypertension, proteinuria, and endothelial dysfunction, is a serious cardiovascular complication in pregnancy (1). Both mother and newborn have a significantly increased future risk for metabolic and cardiovascular diseases as a consequence of a preeclamptic pregnancy (1).

The pathogenesis of PE has been better elucidated in recent years. Thus, dysregulation of angiogenic and anti-angiogenic factors including soluble feline McDonough sarcoma (fms)-like tyrosine kinase 1 and endoglin contribute to the disease (2–5). Furthermore, PE shares features of the metabolic syndrome (1) and recent studies suggest that adipocyte-secreted factors play an important role in the pathogenesis of this pregnancy complication. Among these so-called adipokines, increased concentrations of the appetite-suppressive, adipose tissue-derived factor leptin were found in PE (6). Interestingly, upregulation of leptin precedes the clinical onset of the disease and it has been suggested that hyperleptinemia is a compensatory response to increase nutrient delivery to the underperfused placenta (6, 7). Besides leptin, the proinflammatory adipokine tumour necrosis factor-α (TNF-α) is increased about twofold in women with PE (8). Studies in pregnant rats showed convincingly that this extent of TNF-α upregulation is sufficient to increase mean arterial pressure by 27 mmHg (9). Similar to TNF-α, maternal IL-6 levels are significantly increased threefold in women with PE (8). Furthermore, circulating IL-6 increased from the first to the third trimester in women with PE, but not in healthy pregnant controls (10). In contrast to TNF-α and IL-6, adiponectin is an insulin-sensitizing (11, 12) and anti-atherogenic adipokine (12–14), serum levels of which are decreased when features of the metabolic syndrome including obesity, dyslipidemia, and type 2 diabetes mellitus are present (15). Furthermore, epidemiological data suggest that low levels of adiponectin at baseline are associated with an increased risk to develop type 2 diabetes.
mellitus (15). In contrast, circulating adiponectin is not significantly associated with coronary heart disease in humans (16), despite the fact that this adipokine shows potent anti-atherogenic effects in various animal models (12–14). Interestingly, adiponectin circulates as a trimer (low molecular weight), hexamer (medium molecular weight), and high molecular weight (HMW) form (15) and HMW adiponectin has been postulated as the active form of the adipokine (17, 18). Since cardiometabolic risk is significantly increased in PE, it was hypothesized several years ago that circulating adiponectin might be decreased in this pregnancy-associated disease. However, a paradoxical upregulation of total adiponectin has been presented in various (19–23) but not all studies (24).

In contrast to total adiponectin, little is known about HMW adiponectin concentrations in PE. Furthermore, it has not been elucidated which factors predict HMW adiponectin in this pregnancy complication. Therefore, we determined HMW adiponectin levels in 20 pregnant controls and 16 PE patients using a novel, specific ELISA (25). Furthermore, circulating HMW adiponectin was correlated with clinical and biochemical measures of renal function, glucose, and lipid metabolism, as well as inflammation.

**Subjects and methods**

**Subjects**

For this study, 16 pregnant women with PE and 20 gestational age-matched controls were recruited from the Department of Obstetrics, University of Leipzig. None of the women were in labor at the time of the blood sampling. PE was defined as gestational blood pressure elevation > 140 mmHg systolic or > 90 mmHg diastolic, accompanied by proteinuria in women who were normotensive before 20 weeks of gestation, according to the Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy (26). Body mass index (BMI) was calculated as weight before pregnancy divided by squared height and the BMI of the study population ranged from 16.9 to 30.5 kg/m². The patients were between the ages of 18 and 40 years.

Homeostasis model assessment of insulin resistance (HOMA-IR) was determined as described previously (27). Patients with generalized inflammation, renal diseases, and diabetes mellitus were excluded from the study. The protocol of the study was approved by the local ethics committee and all patients gave written informed consent before taking part.

**Assays**

A venous blood sample was obtained after an overnight fast, immediately separated by centrifugation at 4000 g for 10 min, and frozen at −80 °C. Serum insulin was measured with a two-site chemiluminescent enzyme immunoassay for the Immulite Automated Analyzer (Diagnostic Products, Los Angeles, CA, USA). Circulating HMW adiponectin (Fujirebio, Tokyo, Japan) was determined according to the manufacturer's instructions. The HMW adiponectin ELISA detected adipokine in a range between 0.4 and 50 µg/L. Serum samples were initially diluted 441-fold as recommended by the manufacturer and further dilutions were performed when HMW adiponectin levels were above the detection range (= 50 µg/L x 441 = 22.05 mg/L). While the degree of precision of the HMW adiponectin ELISA system in terms of coefficient of variance (%) of intra-assay was between 2.4 and 3.0%, that of inter-assays was between 4.2 and 5.1% (25). Total adiponectin was determined with a commercial assay system from Mediagnost (Reutlingen, Germany) according to the manufacturer's instructions. Serum creatinine, glucose, free fatty acids (FFA), cholesterol, triglycerides, and C-reactive protein (CRP) were measured by standard laboratory methods in a certified laboratory.

**Statistical analysis**

SPSS software version 11.5 was used for all statistical analyses (SPSS, Chicago, IL, USA). Differences in circulating HMW and total adiponectin between control and PE patients were assessed by Mann–Whitney U test. Correlations were performed using Spearman’s rank correlation method. To adjust the effects of covariates and identify independent relationships, multivariate linear regression analyses were performed. Distribution was tested for normality using Shapiro–Wilk W test and non-normally distributed parameters were logarithmically transformed before multivariate analyses. A P value of <0.05 was considered statistically significant in all analyses.

**Results**

**Circulating HMW adiponectin serum levels are increased in PE patients when compared with controls**

The clinical characteristics of the subgroups studied (control, PE) are summarized in Table 1. All continuous variables are given as median ± interquartile range. Maternal HMW adiponectin levels were significantly increased in subjects with PE (16.03 ± 12.53 mg/l) when compared with healthy pregnant controls (8.09 ± 4.88 mg/l; P < 0.01; Table 1). This difference in circulating HMW adiponectin was also seen after adjustment for BMI (P < 0.01; data not shown). Similarly, total adiponectin concentrations were higher in PE patients (12.15 ± 8.88 mg/l) when compared with healthy pregnant controls (6.75 ± 3.55 mg/L; P < 0.01; Table 1). PE patients were significantly older (33.0 ± 10.0 years) when compared with control subjects (26.5 ± 10.5 years). In contrast, BMI (22.1 ± 4.2 vs 20.3 ± 3.7 kg/m²) and
Table 1 Baseline characteristics of the study population.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>20</td>
<td>16</td>
</tr>
<tr>
<td>HMW adiponectin (mg/l)</td>
<td>8.09 ± 4.63</td>
<td>16.03 ± 12.53*</td>
</tr>
<tr>
<td>Total adiponectin (mg/l)</td>
<td>6.75 ± 3.55</td>
<td>12.15 ± 8.80*</td>
</tr>
<tr>
<td>Age (years)</td>
<td>26.5 ± 10.5</td>
<td>33.0 ± 10.0*</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>20.3 ± 3.7</td>
<td>22.1 ± 4.2</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>105 ± 30</td>
<td>170 ± 34*</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>70 ± 14</td>
<td>102 ± 26*</td>
</tr>
<tr>
<td>Gestational age at blood sampling (days)</td>
<td>215 ± 23</td>
<td>200 ± 47</td>
</tr>
<tr>
<td>Creatinine (μmol/l)</td>
<td>54 ± 17</td>
<td>66 ± 24*</td>
</tr>
<tr>
<td>FG (mmol/l)</td>
<td>3.59 ± 0.58</td>
<td>3.53 ± 0.61</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>0.58 ± 3.53</td>
<td>3.55 ± 12.15</td>
</tr>
<tr>
<td>FFA (pmol/l)</td>
<td>1.95 ± 0.61</td>
<td>1.89 ± 3.27</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>1.65 ± 2.10</td>
<td>7.60 ± 50.45*</td>
</tr>
</tbody>
</table>

BMI, body mass index; CRP, C reactive protein; DBP, diastolic blood pressure; FFA, free fatty acids; FG, fasting glucose; Fl, fasting insulin; HOMA-IR, Homeostasis model assessment of insulin resistance; SBP, systolic blood pressure; TG, triglycerides. Values for median ± interquartile range are shown. *P < 0.05 when compared with control as assessed by Mann–Whitney U test.

Univariate correlations

When all subjects (n = 36) were analyzed, both serum HMW and total adiponectin levels correlated positively with creatinine and negatively with fasting insulin (Table 2). In addition, total adiponectin but not HMW adiponectin positively correlated with SBP and FFA (Table 2). In contrast, no correlation was found between HMW adiponectin and total adiponectin on one hand and age, BMI, DBP, fasting glucose, cholesterol, triglycerides, and CRP on the other hand (Table 2). Interestingly, a significant negative correlation between HMW adiponectin and fasting insulin could also be detected when the two subgroups (control, PE) were studied separately (controls: r = −0.483, P = 0.031; PE: r = −0.550, P = 0.027). Furthermore, HMW adiponectin and total adiponectin serum levels were strongly and positively correlated (Table 2).

Multivariate correlations

In multiple regression analysis including all subjects (n = 36), the association between HMW adiponectin and total adiponectin serum concentrations, and fasting insulin and serum creatinine, remained significant when the two parameters were included in the model (Table 3). Furthermore, PE remained a significant independent predictor of both HMW adiponectin and total adiponectin in multivariate analyses (Table 3). After controlling for PE, fasting insulin predicted HMW adiponectin but not total adiponectin (Table 3). Moreover, the association between HMW adiponectin and total adiponectin on one hand and creatinine on the other hand, was lost after controlling for PE (Table 3).

Discussion

In the current study, we demonstrate that maternal serum concentrations of HMW adiponectin are significantly increased in PE patients when compared with healthy gestational age-matched controls. Using a different experimental approach, a similar finding has recently been obtained by Takemura et al. (28). The authors demonstrate that in their hands median HMW adiponectin levels are 11.2 mg/l in the PE patients when compared with 6.8 mg/l in the controls using an ELISA kit from Daiichi Pure Chemicals (Tokyo, Japan) (28). In addition, we demonstrate that total circulating adiponectin is significantly increased in PE patients in accordance with previous studies (19–23). Furthermore, we show for the first time in pregnant women that HMW adiponectin is positively correlated with creatinine and negatively associated with markers of insulin resistance (fasting insulin and HOMA-IR) in univariate analyses. A negative correlation between HMW adiponectin and fasting insulin is also demonstrated when the subgroups (control, PE) are studied separately. Moreover, we are the first to demonstrate that fasting

Table 2 Univariate correlations with serum high-molecular-weight (HMW) adiponectin and total adiponectin concentrations in all subjects (n = 36).

| Age (years) | 0.205/NS | 0.178/NS |
| BMI (kg/m²) | −0.009/NS | 0.095/NS |
| SBP (mmHg) | 0.279/0.100 | 0.337/0.018* |
| DBP (mmHg) | 0.259/NS | 0.288/0.088 |
| Creatinine (μmol/l) | 0.369/0.027* | 0.392/0.018* |
| FG (mmol/l) | 0.094/NS | 0.096/NS |
| FI (pmol/l) | −0.515/0.001* | −0.392/0.018* |
| HOMA-IR | −0.423/0.010* | −0.316/0.060 |
| FFA (mmol/l) | 0.268/NS | 0.381/0.022* |
| Cholesterol (mmol/l) | −0.216/NS | −0.104/NS |
| TG (mmol/l) | −0.158/NS | −0.106/NS |
| Total adiponectin | 0.910/0.000* | − |
| (mg/l) | − | − |
| HMW adiponectin | 0.910/0.000* | − |
| CRP (mg/l) | 0.228/NS | 0.214/NS |

BMI, body mass index; CRP, C reactive protein; DBP, diastolic blood pressure; FFA, free fatty acids; FG, fasting glucose; Fl, fasting insulin; HOMA-IR, Homeostasis model assessment of insulin resistance; SBP, systolic blood pressure; TG, triglycerides. r/P values are given. NS indicates P > 0.1. *Significant correlation as assessed by Spearman’s correlation method.
serum creatinine is significantly and positively correlated to HMW adiponectin in the current study independent of fasting insulin levels. Furthermore, we show that serum creatinine is significantly increased in PE patients compared with gestational age-matched controls. Taking these data into consideration, it appears plausible that mild renal dysfunction seen as a consequence of PE at least in part contributes to increased circulating HMW adiponectin in this pregnancy-associated disease. This hypothesis is further supported by reports convincingly demonstrating that renal excretion is a physiologically important route of adiponectin clearance with increased levels of this adipokine found in end-stage renal disease (35, 36).

Taken together, we present evidence that maternal HMW adiponectin levels are significantly increased in PE and positively associated with markers of insulin sensitivity and renal dysfunction. Our data support the hypotheses that HMW adiponectin might be part of a physiological feedback mechanism improving insulin sensitivity and cardiovascular health in PE and that renal excretion is a physiological route of HMW adiponectin clearance.

Acknowledgements

This study was supported by a grant from the Deutsche Forschungsgemeinschaft (DFG). KFO 152: ‘Atherobesity’, project FA476/4-1 (TP 4) to M F, project BL833/1-1 (TP3) to M B, and the IZKF Leipzig to M F (Project B25).

References


9 LaMarca BB, Bennett WA, Alexander BT, Cockrell K & Granger JP. Leptin and preeclampsia. *Hypertension* 2002 40 37487–37491.


118


Received 7 November 2007
Accepted 12 November 2007